Total Funding
29
66
Total FundingSeed raised
Growth Score 29 in past quarter
-1 pts
Heat Score 66 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
71352
Thyreos provides prophylactic vaccines for neuroinvasive herpesvirus infections.
- Eric Zeece: Chief Executive Officer
- Ekaterina Heldwein: Co-Founder
About the Company
Thyreos is a company that creates herpesvirus vaccines and vaccine vectors for the animal and human health markets. The vaccines are built on a recombinant herpesvirus platform, which elicits strong immune responses without infecting the nervous system. Periodic reactivation of the latent infection causes the contagious shedding of infectious
viruses, which is frequently associated with mild or severe disease.
Women Founded